Champions Oncology, Inc.
CSBR
$5.96
$0.111.88%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -2.82% | 11.46% | -0.47% | -11.76% | 41.77% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -2.82% | 11.46% | -0.47% | -11.76% | 41.77% |
| Cost of Revenue | 33.50% | -2.23% | 13.05% | 0.29% | -15.70% |
| Gross Profit | -25.88% | 28.25% | -14.15% | -24.70% | 149.93% |
| SG&A Expenses | 34.18% | 36.59% | 5.21% | 6.54% | -7.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.54% | 16.41% | 13.90% | 1.67% | -14.09% |
| Operating Income | -104.16% | -74.73% | -138.15% | -1,145.12% | 274.58% |
| Income Before Tax | -105.25% | -65.49% | -133.88% | -933.68% | 279.36% |
| Income Tax Expenses | 82.61% | 63.64% | -33.33% | -59.26% | 109.09% |
| Earnings from Continuing Operations | -106.21% | -67.45% | -135.49% | -1,583.49% | 277.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.21% | -63.19% | -133.21% | -1,583.49% | 277.67% |
| EBIT | -104.16% | -74.73% | -138.15% | -1,145.12% | 274.58% |
| EBITDA | -96.86% | -52.08% | -108.38% | -312.56% | 333.64% |
| EPS Basic | -106.13% | -63.81% | -132.71% | -1,567.50% | 276.30% |
| Normalized Basic EPS | -103.25% | -59.41% | -128.38% | -771.68% | 277.98% |
| EPS Diluted | -106.48% | -61.20% | -135.11% | -1,195.15% | 263.16% |
| Normalized Diluted EPS | -103.41% | -60.00% | -129.29% | -771.68% | 269.78% |
| Average Basic Shares Outstanding | 1.36% | 1.46% | 1.43% | 1.18% | 0.79% |
| Average Diluted Shares Outstanding | -3.33% | 3.14% | -1.81% | 1.18% | 5.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |